Brief: Mithra Pharmaceuticals signs binding term sheet with Fuji Pharma to commercialize Donesta in Japan and ASEAN
02/03/2017 06:54
March 2 (Reuters) - Mithra Pharmaceuticals SA MITRA.BR :
* Announced on Wednesday signing of a binding term sheet
with the Japanese leader in women's health Fuji Pharma 4554.T
to commercialize Donesta in Japan and ASEAN
* The 20-year partnership agreement, which includes an
exclusive supply agreement by Mithra's CDMO2, should generate
single-digit upfront milestones
* More details on the deal will be communicated when the
full and complete LSA is finalized
* Mithra also provides an update on its Phase II program for
Donesta; has decided to extend the protocol of its Phase II
study
* Regulatory approval of the new protocol is expected
towards the end of Q1 2017. The Phase II study is now expected
to be completed in Q1 2018, and topline results of the Phase II
study should be available late Q1 2018
Source text for Eikon: urn:newsml:reuters.com:*:nNDL650NCW
Further company coverage: MITRA.BR
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))